Skip to main content
SpringerLink
Log in

Lymph Node Metastasis Density and Growth Pattern as Independent Prognostic Factors in Advanced Esophageal Squamous Cell Carcinoma

  • Published:
World Journal of Surgery Aims and scope Submit manuscript

Abstract

Background

Esophageal cancer is one of the leading types of cancer, and it is a particularly deadly form of malignancy. TNM classification is the most common staging system, but it has been reported that prognosis is not reflected adequately by this classification. The purpose of this study was to clarify independent prognostic factors in esophageal squamous cell carcinoma (ESCC), a dominant type of esophageal cancer in Japan, to broaden the staging system to improve its predictive value. Thus staging could be expanded to make the prognosis a valuable clinical tool, and to improve knowledge of the biological traits of advanced ESCC.

Methods

The present study included 121 patients with advanced ESCC (stage II to IVA) treated by esophagectomy between 1990 and 2003 at the Kitasato University Higashi Hospital.

Results

Univariate prognostic analysis of the disease-specific survival revealed that TNM stage (p < 0.0001), lymph node metastasis density over 10% (ND10; p < 0.0001), R-category (p = 0.003), intramural metastasis within the esophagus (IM; p = 0.009), growth pattern (p = 0.01), and size of tumor (p = 0.02) were significantly associated with a poor outcome in advanced ESCC. Multivariate analysis confirmed that growth pattern (p = 0.02, HR = 3.1) and ND10 (p = 0.02, HR = 2.0) were finally remnant prognostic factors independent of TNM stage. Growth pattern was prominent in stage II, whereas ND10 was directly proportional to stage progression and characteristics to stage IV disease. Interestingly, ND20, the most malignant phenotype of ESCC, was the only prognostic determinant, even in stage IV disease.

Conclusions

From the present study, we concluded that progression of lymph node density is characteristic of a life-threatening phenotype of advanced ESCC, and it should be employed as a therapeutic target to improve patient survival. Growth pattern is an alternative target characteristic of less advanced ESCC. Both of these parameters may be applied as useful clinical tools in the management of patients with advanced esophageal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Ferlay J, Bray F, Pisani P et al. (2001) GLOBOCAN2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC Cancer Base No. 5, Lyon, France, IARC Press

  2. Shinoda M, Hatooka S, Mori S, et al. (2006) Clinical aspects of multimodality therapy for resectable locoregional esophageal cancer. Ann Thorac Cardiovasc Surg 12(4):234–241

    PubMed  Google Scholar 

  3. Schneider P, Baldus S, Metzger R, et al. (2005) Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer. Ann Surg 242(5):684–692

    Article  PubMed  Google Scholar 

  4. Union Internationale Contre Le Cancer (2002) TNM Classification of Malignant Tumours, 6th Edition, New York, Wiley-Liss

    Google Scholar 

  5. Japanese Society for Esophageal Disease. (2001) Guidelines for Clinical and Pathological studies on Carcinoma of the Esophagus, 9th Edition, Tokyo, Kanehara and Co, Ltd

    Google Scholar 

  6. Rice T, Blackstone E, Rybicki L, et al. (2003) Refining esophageal cancer staging. J Thorac Cardiovasc Surg 125(5):1103–1113

    Article  PubMed  Google Scholar 

  7. Tachibana M, Kinugasa S, Dhar D, et al. (2001) Dukes’ classification as a useful staging system in resectable squamous cell carcinoma of the esophagus. Virchows Arch 438:350–356

    Article  PubMed  CAS  Google Scholar 

  8. Nozoe T, Sugimachi K (2003) Simple staging criteria for esophageal carcinoma. Am J Clin Oncol 26(3):307–311

    Article  PubMed  Google Scholar 

  9. Kuwano H, Watanabe M, Sadanaga N, et al. (1994) Univariate and multivariate analyses of the prognostic significance of discontinuous intramural metastasis in patients with esophageal cancer. J Surg Oncol 57(1):17–21

    Article  PubMed  CAS  Google Scholar 

  10. Zafirellis K, Dolan K, Fountolakis A, et al. (2002) Multivariate analysis of clinical, operative and pathologic features of esophageal cancer: who needs adjuvant therapy? Dis Esophagus 15:155–159

    Article  PubMed  CAS  Google Scholar 

  11. Siewert JR, Feith M, Werner M, et al. (2000) Adenocarcinoma based on anatomical topographical classification in 1,002 patients. Ann Surg 232:353–361

    Article  Google Scholar 

  12. Brucher B, Stein H, Werner M, et al. (2001) Lymphatic vessel invasion is an independent prognostic factor in patients with a primary resected tumor with esophageal squamous cell carcinoma. Cancer 92:2228–2233

    Article  PubMed  CAS  Google Scholar 

  13. Roder JD, Busch R, Stein HJ, et al. (1994) Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. Br J Surg 81:410–413

    Article  PubMed  CAS  Google Scholar 

  14. Tachibana M, Dhar DK, Kinugasa S, et al. (2000) Esophageal cancer with distant lymph node metastases: prognostic significance of metastatic lymph node ratio. J Clin Gastroenterol 31:318–322

    Article  PubMed  CAS  Google Scholar 

  15. Peto R, Pike MC, Armitage P, et al. (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1–39

    PubMed  CAS  Google Scholar 

  16. Cox DR (1972) Regression models and life tables. J R Stat Soc 34:1987–2001

    Google Scholar 

  17. Hosch SB, Izbicki JR, Pichlmeier U, et al. (1997) Expression and prognostic significance of immunoregulatory molecules in esophageal cancer. Int J Cancer 74:582–587

    Article  PubMed  CAS  Google Scholar 

  18. Algarra I, Garcia-Lora A, Cabrera T, et al. (2004) The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 53(10):904–910

    Article  PubMed  CAS  Google Scholar 

  19. Seliger B (2005) Strategies of tumor immune evasion. Bio Drugs 19(6):347–354

    CAS  Google Scholar 

  20. Tomimaru Y, Yano M, Takachi K, et al. (2006) Plasma D-dimer levels show correlation with number of lymph node metastases in patients with esophageal cancer. J Am Coll Surg 202(1):139–145

    Article  PubMed  Google Scholar 

  21. Javle MM, Nwogu CE, Donohue KA, et al. (2006) Management of locoregional stage esophageal cancer: a single center experience. Dis Esophagus 19:78–83

    Article  PubMed  CAS  Google Scholar 

  22. Khushalani NI, Leichman CG, Proulx G, et al. (2002) Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol 20:2844–2850

    Article  PubMed  CAS  Google Scholar 

  23. Tew WP, Minsly B, Bains M et al. (2005) Phase II trial of preoperative combined modality therapy for esophageal carcinoma: induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy. 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL. Proc Am Soc Clin Oncol 23 (16S) Part I of II: abstract 4015

  24. Kadowaki T, Shiozaki H, Inoue M, et al. (1994) E-cadherin and alpha-catenin expression in human esophageal cancer. Cancer Res 54(1):291–296

    PubMed  CAS  Google Scholar 

  25. Tamura S, Shiozaki H, Miyata M, et al. (1996) Decreased E-cadherin expression is associated with haematogenous recurrence and poor prognosis in patients with squamous cell carcinoma of the oesophagus. Br J Surg 83(11):1608–1614

    Article  PubMed  CAS  Google Scholar 

  26. Lin YC, Wu MY, Li DR, et al. (2004) Prognostic and clinicopathological features of E-cadherin, alpha-catenin, beta-catenin, gamma-catenin and cyclin D1 expression in human esophageal squamous cell carcinoma. World J Gastroenterol 10(22):3235–3239

    PubMed  CAS  Google Scholar 

  27. Zhao XJ, Li H, Chen H, et al. (2003) Expression of e-cadherin and beta-catenin in human esophageal squamous cell carcinoma: relationships with prognosis. World J Gastroenterol 9(2):225–232

    PubMed  CAS  Google Scholar 

  28. Zhou XB, Lu N, Zhang W, et al. (2002) Expression and significance of beta-catenin in esophageal carcinoma. Ai Zheng 21:877–880

    PubMed  Google Scholar 

  29. Takayama N, Arima S, Haraoka S, et al. (2003) Relationship between the expression of adhesion molecules in primary esophageal squamous cell carcinoma and metastatic lymph nodes. Anticancer Res 23:4435–4442

    PubMed  CAS  Google Scholar 

  30. Zhang G, Zhou X, Xue L, et al. (2005) Accumulation of cytoplasmic beta-catenin correlates with reduced expression of E-cadherin, but not with phosphorylated Akt in esophageal squamous cell carcinoma: immunohistochemical study. Pathol Int 55:310–317

    Article  PubMed  CAS  Google Scholar 

  31. Takeno S, Noguchi T, Fumoto S, et al. (2004) E-cadherin expression in patients with esophageal squamous cell carcinoma: promoter hypermethylation, snail overexpression, and clinicopathologic implication. Am J Clin Pathol 122:78–84

    Article  PubMed  CAS  Google Scholar 

  32. Uchikado Y, Natsugoe S, Okumura H, et al. (2005) Slug expression in the E-cadherin preserved tumors is related to prognosis in patients with esophageal squamous cell carcinoma. Clin Cancer Res 11(3):1174–1180

    PubMed  CAS  Google Scholar 

  33. Lioni M, Brafford P, Claudia A, et al. (2007) Dysregulation of claudin-7 leads to loss of E-cadherin expression and the increased invasion of esophageal squamous cell carcinoma cells. Am J Pathol 170(2):709–721

    Article  PubMed  CAS  Google Scholar 

  34. Kim JS, Crooks H, Foxworth A, et al. (2002) Proof-of-principle: oncogenic beta-catenin is a valid molecular target for the development of pharmacological inhibitors. Mol Cancer Ther 1(14):1355–1359

    PubMed  CAS  Google Scholar 

  35. Cong F, Zhang J, Pao W, et al. (2003) A protein knockdown strategy to study the function of beta-catenin in tumorigenesis. BMC Mol Biol 4:10

    Article  PubMed  Google Scholar 

  36. Emami K, Mguyen C, Ma H, et al. (2004) A small molecule inhibitor of beta-catenin/cyclic AMP response element-binding protein transcription. Proc Natl Acad Sci USA 101(34):12682–12687

    Article  PubMed  CAS  Google Scholar 

  37. Dillard AC, Lane MA (2007) Retinol decreases beta-catenin protein levels in retinoic acid resistant colon cancer cell lines. Mol Carcinog 46:315–329

    Article  PubMed  CAS  Google Scholar 

  38. Korst RJ, Kansler A, Port J, et al. (2006) Downstaging of T or N predicts long-term survival after preoperative chemotherapy and radical resection for esophageal carcinoma. Ann Thorac Surg 82:480–485

    Article  PubMed  Google Scholar 

  39. Brucher B, Becker K, Lordick F, et al. (2006) The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer 106:2119–2127

    Article  PubMed  Google Scholar 

  40. Swisher S, Hofstetter W, Wu T, et al. (2005) Proposed Revision of the Esophageal Cancer Staging System to Accommodate Pathologic Response (pP) Following Preoperative Chemoradiation (CRT). Ann Surg 241(5):810–820

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Kitasato University Higashi Hospital, Asamizodai 2-1-1, Sagamihara, 228-8520, Kanagawa, Japan

    Akira Ooki, Keishi Yamashita, Nobuyuki Kobayashi, Natsuya Katada, Shinichi Sakuramoto, Shiroh Kikuchi & Masahiko Watanabe

Authors
  1. Akira Ooki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keishi Yamashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nobuyuki Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Natsuya Katada
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shinichi Sakuramoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shiroh Kikuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masahiko Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masahiko Watanabe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ooki, A., Yamashita, K., Kobayashi, N. et al. Lymph Node Metastasis Density and Growth Pattern as Independent Prognostic Factors in Advanced Esophageal Squamous Cell Carcinoma. World J Surg 31, 2184–2191 (2007). https://doi.org/10.1007/s00268-007-9198-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-007-9198-9

Keywords

Search

Navigation